Ipilimumab vs Pazopanib

## Ipilimumab vs Pazopanib: Overview

This comparison examines the pharmacological differences between **Ipilimumab** and **Pazopanib**.

## Mechanism of Action

**Ipilimumab**: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

## Pharmacokinetics

**Half-life**: Ipilimumab — 14.7 days; Pazopanib — N/A.

## Chemical Properties

**Type**: Ipilimumab — Antibody; Pazopanib — Small molecule.